Allergen immunotherapy for allergic respiratory diseases

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 10, 2012, Pages 1499-1512

  Cappella, Antonio ^a   Durham, Stephen R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Adjuvant; Allergen vaccine; Immunopotentiator; Sublingual immunotherapy; Vector system

Indexed keywords

EID: 84868297313     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21629     Document Type: Review

References (150)

1. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11:586-93; PMID:21986550; http://dx.doi.org/10.1097/ACI.0b013e32834cb994.
2. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125(Suppl 2):S306-13; PMID:20176266; http://dx.doi.org/10.1016/j.jaci.2009.10.064.
3. Calderon M, Brandt T. Treatment of grass pollen allergy: focus on a standardized grass allergen extract -GrazaxR. Ther Clin Risk Manag 2008; 4:1255-60; PMID:19337432.
4. Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC, et al.; British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41:1177-200; PMID:21848757; http://dx.doi.org/10.1111/j.1365-2222.2011.03794.x.
5. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 177:1572-3; http://dx.doi.org/10.1016/S0140-6736(00)78276-6.
6. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N Engl J Med 1965; 273:675-9; PMID:5318212; http://dx.doi.org/10.1056/NEJM196509232731302.
7. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986; 16:483-91; PMID:3536171; http://dx.doi.org/10.1111/j.1365-2222.1986.tb01983.x.
8. Black JH. The oral administration of pollen. J Lab Clin Med 1927; 12:1156.
9. Black JH. The oral administration of pollen: clinical report. J Lab Clin Med 1928; 13:709.
10. Committee on the safety of medicines. CSM update. Desensitizing vaccines. BMJ 1986; 293:948; PMID:20742706; http://dx.doi.org/10.1136/bmj.293.6552.948.
11. Malling H, Weeke B; Position Paper of the European Academy of Allergy and Clinical Immunology. Position paper: Immunotherapy. Allergy 1993; 48(Suppl):9-35; PMID:8342741; http://dx.doi.org/10.1111/j.1398-9995.1993. tb04754.x.
12. Bousquet J, Lockey R, Malling HJ. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 53:1-42.
13. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al.; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA)2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(Suppl 86):8-160; PMID:18331513; http://dx.doi.org/10.1111/j.1398-9995.2007.01620.x.
14. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; CD001936; PMID:17253469.
15. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:319-25; PMID:16461133; http://dx.doi.org/10.1016/j.jaci.2005. 11.014.
16. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebocontrolled trial. Clin Exp Allergy 2003; 33:1076-82; PMID:12911781; http://dx.doi.org/10.1046/j.1365-2222. 2003.01735.x.
17. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54:1022-41; PMID:10536881; http://dx.doi.org/ 10.1034/j.1398-9995.1999.00102.x.
18. Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990; 86:292-305; PMID:2212405; http://dx.doi.org/10.1016/ S0091-6749(05)80091-0.
19. Cantani A, Arcese G, Lucenti P, Gagliesi D, Bartolucci M. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol 1997; 7:90-7; PMID:9161933.
20. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; CD001186; PMID:20687065.
21. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM; Regione Veneto Study Group on the "Effect of immunotherapy in allergic asthma". Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004; 113:643-9; PMID:15100667; http://dx.doi.org/10.1016/j.jaci.2003.12.586.
22. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010; 126:942-9; PMID:20624650; http://dx.doi.org/10.1016/j.jaci.2010.06.002.
23. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62; PMID:9802362; http://dx.doi.org/10.1016/S0091-6749(98)70271-4.
24. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT)and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-77; PMID:3559001; http://dx.doi.org/10.1016/S0091-6749(87)80164-1.
25. Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010; 65:1525-30; http://dx.doi.org/ 10.1111/j.1398-9995.2010.02474.x; PMID:21039596.
26. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003; CD002893; PMID:12804442.
27. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740-52; PMID:21443635; http://dx.doi.org/10.1111/j.1398-9995.2011.02583.x.
28. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-73.e7; PMID:19130937; http://dx.doi.org/10.1016/j.jaci.2008.10.044.
29. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al.; SLIT Study Group. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160-6.e3; PMID:19046761; http://dx.doi.org/10.1016/j.jaci.2008.10.009.
30. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 2005; 15:9-16; PMID:15864877.
31. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-8; PMID:16937742; http://dx.doi.org/10.1016/S1081-1206(10)60004-X.
32. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-21; PMID:12787302; http://dx.doi.org/10.1034/j. 1399-3038.2003.00025.x.
33. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr)1990; 18:277-84; PMID:2097894.
34. Hirsch Th, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.)in children. Pediatr Allergy Immunol 1997; 8:21-7; PMID:9260215; http://dx.doi.org/10.1111/j. 1399-3038.1997. tb00138.x.
35. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebocontrolled study. Pediatr Pulmonol 2001; 32:49-55; PMID:11416876; http://dx.doi.org/10.1002/ppul.1088.
36. Blaiss M, Maloney J. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. American Academy of Allergy, Asthma & Immunology
37. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009; 64:1570-9; PMID:19796205; http://dx.doi.org/10.1111/j.1398-9995.2009.02129.x.
38. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162-72; PMID:16942563; http://dx.doi.org/10.1111/j.1398-9995.2006.01205.x.
39. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-8; PMID:16937742; http://dx.doi.org/10.1016/S1081-1206(10)60004-X.
40. Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009; 39:387-93; PMID:19134019; http://dx.doi.org/10.1111/j.1365- 2222.2008.03152.x.
41. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:565-71; PMID:15898976; http://dx.doi.org/10.1111/j. 1365-2222.2005.02240.x.
42. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021-35; PMID:16675328; http://dx.doi.org/10.1016/j.jaci.2006.02.040.
43. Lombardi C, Gargioni S, Cottini M, Canonica GW, Passalacqua G. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008; 63:375-6; PMID:18269680; http://dx.doi.org/10.1111/j.1398-9995.2007.01608.x.
44. Passalacqua G, Pawankar R, Baena-Cagnani CE, Canonica GW. Sublingual immunotherapy: where do we stand? Present and future. Curr Opin Allergy Clin Immunol 2009; 9:1-3; PMID:19106697; http://dx.doi.org/10.1097/ACI. 0b013e3283196a9b.
45. Rodriguez-Perez N, Ambriz-Moreno MdeJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:304-10; PMID:18814454; http://dx.doi.org/10.1016/S1081-1206(10)60496-6.
46. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125:569-74, 574.e1-574.e7; PMID:20144472; http://dx.doi.org/10.1016/j.jaci.2009.10.060.
47. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61:1235; PMID:16942576; http://dx.doi.org/10.1111/j.1398-9995.2006.01137.x.
48. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236-7; PMID:16942577; http://dx.doi.org/10. 1111/j.1398-9995.2006.01155.x.
49. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62:567-8; PMID:17313400; http://dx.doi.org/10.1111/j.1398-9995.2006.01301.x.
50. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63:374; PMID:18076729; http://dx.doi.org/10.1111/j.1398-9995.2007.01563.x.
51. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64:963-4; PMID:19222420; http://dx.doi.org/10.1111/j.1398-9995.2009.01998.x.
52. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:430-3; PMID:8837669; http://dx.doi.org/10.1111/j.1398-9995.1996.tb00155.x.
53. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984; 14:209-19; PMID:6375890; http://dx.doi.org/10.1111/j.1365-2222.1984.tb02200.x.
54. Naclerio RM, Proud D, Moylan B, Balcer S, Freidhoff L, Kagey-Sobotka A, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100:293-300; PMID:9314339; http://dx.doi.org/10.1016/ S0091-6749(97)70240-9.
55. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75; PMID:10441602; http://dx.doi.org/10.1056/NEJM199908123410702.
56. Tabar AI, Arroabarren E, Echechipia S, Garcia BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011; 127:57-63. e1-3; PMID:21211641; http://dx.doi.org/10.1016/j.jaci.2010.10.025.
57. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al.; (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8; PMID:17620073; http://dx.doi.org/10.1111/j.1398- 9995.2007.01451.x.
58. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61:198-201; PMID:16409196; http://dx.doi.org/10.1111/j.1398-9995. 2006.01011.x.
59. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33:206-10; PMID:12580913; http://dx.doi.org/10.1046/j.1365-2222.2003.01587.x.
60. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003; 16:73-9; PMID:12578735.
61. Ott H, Sieber J, Brehler R, Folster-Holst R, Kapp A, Klimek L, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009; 64:179-86; PMID:19076534; http://dx.doi.org/10.1111/j.1398-9995.2008.01875.x.
62. Durham SR, Emminger W, Kapp A, Colombo G, De Monchy JG, Rak S, et al. Longterm clinical efficacy in grass polleninduced rhinoconjunctivitis after treatment with SQstandardized grass allergy immunotherapy tablet. J Allergy Clin Immunol2010;125:1318.
63. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmaiton of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-25 e5; PMID: 22285278; http://dx.doi.org/10.1016/j. jaci.2011.12.973.
64. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al.; SLIT Study Group. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160-6.e3; PMID:19046761; http://dx.doi.org/10.1016/j.jaci.2008.10.009.
65. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126:969-75; PMID:20934206; http://dx.doi.org/10.1016/j.jaci.2010.08.030.
66. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75; PMID:10441602; http://dx.doi.org/10.1056/NEJM199908123410702.
67. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51; PMID:8349803; http://dx.doi.org/10.1172/JCI116633.
68. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-75; PMID:10069882; http://dx.doi.org/10.1016/S0091-6749(99)70473-2.
69. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994; 93:484-93; PMID:8120276; http://dx.doi.org/10.1016/0091-6749(94)90358-1.
70. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105:56-62; PMID:11849315; http://dx.doi.org/10.1046/j.1365-2567.2002.01338.x.
71. Scadding G, Durham S. Mechanisms of sublingual immunotherapy. J Asthma 2009; 46:322-34; PMID:19484663; http://dx.doi.org/10.1080/02770900902785729.
72. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-14; PMID:12731045; http://dx.doi.org/10.1002/eji.200322919.
73. Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH, Hawrylowicz CM. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin Exp Allergy 2003; 33:1209-15; PMID:12956740; http://dx.doi.org/10.1046/j.1365-2222.2003.01748.x.
74. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105:56-62; PMID:11849315; http://dx.doi.org/10.1046/j.1365-2567.2002.01338.x.
75. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61; PMID:12789226; http://dx.doi.org/10.1067/mai.2003.1570.
76. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65; PMID:8648033; http://dx.doi.org/10.1016/S0091-6749(96)70205-1.
77. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy 2011; 41:1235-46; PMID:21762223; http://dx.doi.org/10.1111/j.1365- 2222.2011.03804.x.
78. de Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, Willart MA, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200:89-98; PMID:15238608; http://dx.doi.org/10.1084/jem.20040035.
79. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106; PMID:9649562; http://dx.doi.org/10.1172/JCI2250.
80. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-22; PMID:1940369.
81. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10)inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20; PMID:1940799; http://dx.doi.org/10.1084/jem.174.5.1209.
82. Hsu DH, Moore KW, Spits H. Differential effects of interleukin-4 and -10 on interleukin-2 induced interferon-+ synthesis and lymphokine activated killer activity. Int Immunol 1992; 4:563-9; PMID:1627494; http://dx.doi.org/10.1093/ intimm/4.5.563.
83. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1)and type 2 helper (Th2)T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150:353-60; PMID:8419468.
84. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-5.e2; PMID:18374405; http://dx.doi.org/10.1016/j.jaci.2008.01. 072.
85. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002; 195:1499-505; PMID:12045248; http://dx.doi.org/10.1084/jem.20012076.
86. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGFbeta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000; 165:4773-7; PMID:11045997.
87. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178:4658-66; PMID:17372025.
88. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172:5149-53; PMID:15100250.
89. Oida T, Xu L, Weiner HL, Kitani A, Strober W. TGFbeta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol 2006; 177:2331-9; PMID:16887994.
90. Grindebacke H, Larsson P, Wing K, Rak S, Rudin A. Specific immunotherapy to birch allergen does not enhance suppression of Th2 cells by CD4(+)CD25(+)regulatory T cells during pollen season. J Clin Immunol 2009; 29:752-60; PMID:19543958; http://dx.doi.org/10.1007/s10875-009-9312-x.
91. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-72, 1472. e1; PMID:18423565; http://dx.doi.org/10.1016/j.jaci.2008.03.013.
92. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178:4658-66; PMID:17372025.
93. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116:73-9; PMID:15990777; http://dx.doi.org/10.1016/j.jaci.2005.03.011.
94. Wilson DR, Irani AM, Walker SM, Jacobson MR, Mackay IS, Schwartz LB, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-13; PMID:11696046; http://dx.doi.org/10.1046/j.1365-2222.2001.01231.x.
95. Van Ree R, Van Leeuwen WA, Dieges PH, Van Wijk RG, De Jong N, Brewczyski PZ, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5)during immunotherapy. Clin Exp Allergy 1997; 27:68-74; PMID:9117883; http://dx.doi.org/10.1046/j.1365-2222.1997.d01-416.x.
96. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472-82; PMID:4119162; http://dx.doi.org/10.1172/JCI107204.
97. Devey ME, Wilson DV, Wheeler AW. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin Allergy 1976; 6:227-36; PMID:939035; http://dx.doi.org/10.1111/j.1365-2222. 1976.tb01901.x.
98. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-208; PMID:12956739; http://dx.doi.org/10.1046/j.1365-2222. 2003.01699.x.
99. Garcia BE, Sanz ML, Dieguez I, de las Marinas MD, Oehling A. Modifications in IgG subclasses in the course of immunotherapy with grass pollen. J Investig Allergol Clin Immunol 1993; 3:19-25; PMID:8281327.
100. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy 2006; 36:273-82; PMID:16499637; http://dx.doi.org/10.1111/j.1365-2222. 2006.02442.x.
101. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915-22; PMID:14610480; http://dx.doi.org/10.1016/S0091- 6749(03)02022-0.
102. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-9; PMID:14978133.
103. Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010; 40:1346-52; PMID:20604801; http://dx.doi.org/10.1111/j.1365-2222. 2010.03548.x.
104. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606; PMID:20184605.
105. Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol 2005; 174:4718-26; PMID:15814696.
106. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178:4658-66; PMID:17372025.
107. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-14; PMID:12731045; http://dx.doi.org/10.1002/eji.200322919.
108. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002; 57:423-30; PMID:11972482; http://dx.doi.org/10.1034/j.1398-9995. 2002.13248.x.
109. Gehlar K, Schlaak M, Becker W-M, Buffe A. Monitoring allergen Immunotherapy Mechanisms of immunotherapy to aeroallergens of pollen-allergic patients: The ration of allergen-specificIgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999; 29:497-506; PMID:10202364; http://dx.doi.org/10. 1046/j.1365-2222.1999.00525.x.
110. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97-101; PMID:11729346; http://dx.doi.org/10.1159/000049499.
111. Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63:720-7; PMID:18445186; http://dx.doi.org/10.1111/j.1398-9995.2007.01611.x.
112. Allam JP, Novak N, Fuchs C, Asen S, Berge S, Appel T, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:141-8; PMID:12847491; http://dx.doi.org/10.1067/mai.2003.1607.
113. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65; PMID:16409190; http://dx.doi.org/10.1111/j.1398-9995.2006.01002.x.
114. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med 2008; 14:191-8; PMID:18396104; http://dx.doi.org/10. 1016/j.molmed.2008.03.001.
115. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603-9.e5; PMID:18774396; http://dx.doi.org/10.1016/j.jaci.2008.06.034.
116. Novak N, Bieber T, Katoh N. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 2001; 167:797-804; PMID:11441085.
117. von Bubnoff D, Matz H, Frahnert C, Rao ML, Hanau D, de la Salle H, et al. FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J Immunol 2002; 169:1810-6; PMID:12165503.
118. Novak N, Bieber T, Katoh N. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 2001; 167:797-804; PMID:11441085.
119. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606; PMID:20184605.
120. Nieminen K, Laaksonen K, Savolainen J. Threeyear follow-up study of allergen-induced in vitro cytokine and signalling lymphocytic activation molecule mRNA responses in peripheral blood mononuclear cells of allergic rhinitis patients undergoing specific immunotherapy. Int Arch Allergy Immunol 2009; 150:370-6; PMID:19571569; http://dx.doi.org/10.1159/000226238.
121. Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 2003; 112:1171-7; PMID:14657878; http://dx.doi.org/10.1016/j.jaci.2003.08.043.
122. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351:629-32; PMID:9500318; http://dx.doi.org/10.1016/S0140-6736(97)07055-4.
123. Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120:218-24; PMID:10592467; http://dx.doi.org/10.1159/000024270.
124. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-15; PMID:9678832; http://dx.doi.org/10.1111/j.1365-2222. 1997.tb01252.x.
125. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid downregulates allergen-specific immunoglobulin E and increases both interferon-gamma-and interleukin-10-production. Clin Exp Allergy 2006; 36:261-72; PMID:16499636; http://dx.doi.org/10.1111/j.1365-2222.2006.02429.x.
126. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergeninduced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61:1184-90; PMID:16942566; http://dx.doi.org/10.1111/j.1398-9995. 2006.01206.x.
127. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-13; PMID:17681368; http://dx.doi.org/10.1016/j.jaci.2007.06.013.
128. Savolainen J, Nieminen K, Laaksonen K, Laiho T, Jacobsen L, Lahesmaa R, et al. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007; 62:949-53; PMID:17620074; http://dx.doi.org/10.1111/j.1398-9995.2007.01426.x.
129. Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-41; PMID:15650310; http://dx.doi.org/10.1159/000083320.
130. Piconi S, Trabattoni D, Rainone V, Borgonovo L, Passerini S, Rizzardini G, et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J Immunol 2010; 185:7723-30; PMID:21076061; http://dx.doi.org/10.4049/ jimmunol.1002465.
131. Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-8; PMID:10550740; http://dx.doi.org/10.1016/S0091-6749(99) 70076-X.
132. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007; 62:954-7; PMID:17620075; http://dx.doi.org/10.1111/j.1398-9995.2007.01402. x.
133. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007; 62:958-61; PMID:17620076; http://dx.doi.org/10.1111/j. 1398-9995.2007.01416.x.
134. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915-22; PMID:14610480; http://dx.doi.org/10.1016/S0091- 6749(03)02022-0.
135. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy 2006; 36:273-82; PMID:16499637; http://dx.doi.org/10.1111/j.1365-2222. 2006.02442.x.
136. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606; PMID:20184605.
137. O'Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180:936-47; PMID:19696440; http://dx.doi.org/10.1164/rccm.200905-0686OC.
138. Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001; 22:175-8; PMID:11274910; http://dx.doi.org/10.1016/S1471-4906(01)01862-2.
139. Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001; 22:175-8; PMID:11274910; http://dx.doi.org/10.1016/S1471-4906(01)01862-2.
140. Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, Mannhart C, et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005; 115:323-9; PMID:15696088; http://dx.doi.org/10.1016/j.jaci.2004.11.041.
141. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:449-59; PMID:6171586; http://dx.doi.org/10.1016/0091-6749(81)90199-8.
142. Karamloo F, Schmid-Grendelmeier P, Kussebi F, Akdis M, Salagianni M, von Beust BR, et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005; 35:3268-76; PMID:16206231; http://dx.doi.org/10.1002/eji.200425522.
143. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101(Suppl 2):14677-82; PMID:15310844; http://dx.doi.org/10.1073/pnas.0404735101.
144. Larche M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006; 18:745-50; PMID:17010586; http://dx.doi.org/10.1016/j.coi.2006.09.013.
145. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113:1144-51; PMID:15208597; http://dx.doi.org/10.1016/j.jaci.2004.03.003.
146. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235-41; PMID:14767435; http://dx.doi.org/10.1016/j.jaci.2003.11.001.
147. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498-505; PMID:11421893; http://dx.doi.org/10.1034/j.1398-9995. 2001.056006498.x.
148. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608-13; PMID:16159631; http://dx.doi.org/10.1016/ j.jaci.2005.06.004.
149. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al.; Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:688-95; PMID:17631952; http://dx.doi.org/10.1016/j.jaci.2007.05.034.
150. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008; 105:17908-12; PMID:19001265; http://dx.doi.org/10.1073/pnas.0803725105.